GSK Lapatinib Breast Cancer Development Shifts To Front-Line Setting
Executive Summary
GlaxoSmithKline will shift its plans for the breast cancer agent lapatinib to focus on front-line use rather than refractory patients, the company said May 15
You may also be interested in...
GSK Oncology Pipeline Expansion Means Healthy Phase III Program In ’06
GlaxoSmithKline's strategy of building its oncology business is paying off with a range of new chemical entities entering Phase III development within the next year for cancer-related indications, executives said during an oncology R&D update in New York
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011